Aktuellt
SENASTE
Callidita’s strict Tarpeyo (US) product growth is 130% in Q3, and the recorded Q3 sales are 12% below our expectations and 9% below consensus. The number of enrolled patients is 10% below our expectations, and the number of new unique subscribers is 2% below our expectations. The 2023 full sales outlook is re-iterated. The following key milestone is the PDUFA day on 20 December, where we expect Calliditas to secure unconditional approval and an expanded label supported by the solid 2-year eGFR results.
LÄS MER
